Coloplast A/S (OTCMKTS:CLPBY) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Coloplast A/S (OTCMKTS:CLPBY) announced its quarterly earnings data on Tuesday. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.01), Zacks reports. Coloplast A/S had a net margin of 18.69% and a return on equity of 30.19%. Coloplast A/S updated its FY 2025 guidance to EPS.

Coloplast A/S Price Performance

OTCMKTS CLPBY opened at $11.13 on Wednesday. The company has a current ratio of 1.02, a quick ratio of 0.66 and a debt-to-equity ratio of 0.92. The business’s fifty day moving average is $11.43 and its 200 day moving average is $12.56. Coloplast A/S has a fifty-two week low of $10.63 and a fifty-two week high of $14.34.

Coloplast A/S Increases Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Stockholders of record on Monday, December 9th were paid a $0.2435 dividend. This is a boost from Coloplast A/S’s previous dividend of $0.05. The ex-dividend date of this dividend was Monday, December 9th. Coloplast A/S’s dividend payout ratio is currently 93.94%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on CLPBY shares. Hsbc Global Res upgraded Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research note on Monday, November 18th. UBS Group upgraded Coloplast A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, Sanford C. Bernstein upgraded Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 28th.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.